Literature DB >> 7260917

Role of glutathione in the metabolism-dependent toxicity and chemotherapy of cyclophosphamide.

H L Gurtoo, J H Hipkens, S D Sharma.   

Abstract

The role of glutathione in the biological effects of cyclophosphamide (CP) was evaluated by investigating the following: effect of CP on hepatic glutathione levels; relationship between hepatic glutathione depletion (repletion) and the binding of [chloroethyl-3H]CP and [4-14C]CP to hepatic macromolecules; effects of interaction between CP (or acrolein) and diethyl maleate (a classical glutathione depletor), and/or between CP and cysteine on the binding of labeled CP to hepatic macromolecules, on the induction of hematuria, on the content of hepatic cytochrome P-450, on weight gain in rats, on survival in mice, and on the chemotherapeutic efficacy of CP against Walker 256 carcinoma in rats. CP and acrolein produced dose-dependent depletion of hepatic glutathione in mice, whereas phosphoramide mustard was at least one order of magnitude less effective. Acrolein caused death in mice; CP became covalently bound to hepatic macromolecules, prevented weight gain in rats, and produced hematuria and depression of hepatic cytochrome P-450 in vivo. These effects of CP (or acrolein) were enhanced by diethyl maleate but partially blocked by cysteine. On the other hand, reduction in the volume of Walker 256 carcinoma in rats by CP was not antagonized by cysteine. All these investigations point to the following conclusions: (a) acrolein produced during the metabolism of CP binds to proteins and, by doing so may denature these proteins; and (b) acrolein in vivo preferentially reacts with glutathione, and sulfhydryl-containing compounds may protect against acrolein toxicity and at the same time not interfere with the chemotherapeutic activity of CP.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7260917

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  26 in total

1.  Changes in plasma amino acids during conditioning therapy prior to bone marrow transplantation: Their relevance to antioxidant status.

Authors:  A G Hunnisett; A Kars; J M Howard; S Davies
Journal:  Amino Acids       Date:  1993-02       Impact factor: 3.520

Review 2.  Cyclophosphamide toxicity. Characterising and avoiding the problem.

Authors:  L H Fraiser; S Kanekal; J P Kehrer
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

3.  Interaction of N-acetylcysteine and bleomycin on hyperbaric oxygen-induced lung damage in mice.

Authors:  D D Jamieson; D R Kerr; I Unsworth
Journal:  Lung       Date:  1987       Impact factor: 2.584

4.  Cellular glutathione as a protective agent against 4-hydroperoxycyclophosphamide cytotoxicity in K-562 cells.

Authors:  R H Peters; K Ballard; J E Oatis; D J Jollow; R K Stuart
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

5.  Prevention of cyclophosphamide-induced urotoxicity by reduced glutathione and its effect on acute toxicity and antitumor activity of the alkylating agent.

Authors:  O Tofanetti; E Cavalletti; A Besati; G Pratesi; G Pezzoni; F Zunino
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

6.  Formation, toxicity and inactivation of acrolein during biotransformation of cyclophosphamide as studied in freshly isolated cells from rat liver and kidney.

Authors:  Y Ohno; K Ormstad
Journal:  Arch Toxicol       Date:  1985-06       Impact factor: 5.153

7.  Curculigo orchioides Gaertn Effectively Ameliorates the Uro- and Nephrotoxicities Induced by Cyclophosphamide Administration in Experimental Animals.

Authors:  Vishnu Priya Murali; Girija Kuttan
Journal:  Integr Cancer Ther       Date:  2015-09-29       Impact factor: 3.279

8.  Effect of etoposide (VP16-213) on lipid peroxidation and antioxidant status in a high-dose radiochemotherapy regimen.

Authors:  C Ladner; G Ehninger; K F Gey; M R Clemens
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

9.  Acacia Senegal gum exudate offers protection against cyclophosphamide-induced urinary bladder cytotoxicity.

Authors:  Abdulaziz A Al-Yahya; Abdulhakeem A Al-Majed; Ali M Gado; Mohammad H Daba; Othman A Al-Shabanah; Adel R A Abd-Allah
Journal:  Oxid Med Cell Longev       Date:  2009 Sep-Oct       Impact factor: 6.543

10.  L-cysteine prodrug protects against cyclophosphamide urotoxicity without compromising therapeutic activity.

Authors:  J C Roberts; D J Francetic; R T Zera
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.